Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amprenavir

FDA-approved product (capsule, oral), marketed as Agenerase.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amprenavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amprenavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amprenavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

    NCT01252940 · start 2010-11

    Registered record
    Registry ID
    NCT01252940
    Conditions
    HIV-1 Infection
    Interventions
    FTC/RPV/TDF; PI; RTV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2014-10
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionFTC/RPV/TDF; PI; RTV; NRTIs
    PhasePhase 3
    Registry statusCompleted

  • HIV Treatment and CVD Events

    NCT01054638 · start 2009-03

    Registered record
    Registry ID
    NCT01054638
    Conditions
    HIV Infection; Cardiovascular Disease; Infection, Human Immunodeficiency Virus; Acute Myocardial Infarction
    Interventions
    HAART Treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Cardiovascular Disease; Infection, Human Immunodeficiency Virus; Acute Myocardial Infarction
    InterventionHAART Treatment
    PhaseNot recorded
    Registry statusCompleted

  • An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

    NCT00802074 · start 2008-12

    Registered record
    Registry ID
    NCT00802074
    Conditions
    Healthy
    Interventions
    Raltegravir; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRaltegravir; Fosamprenavir; Ritonavir
    PhaseNot applicable
    Registry statusCompleted

  • An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

    NCT00614991 · start 2008-01

    Registered record
    Registry ID
    NCT00614991
    Conditions
    Healthy
    Interventions
    Raltegravir; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-03
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRaltegravir; Fosamprenavir; Ritonavir
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Trial of CNS-targeted HAART (CIT2)

    NCT00624195 · start 2007-03

    Registered record
    Registry ID
    NCT00624195
    Conditions
    HIV Infections
    Interventions
    FDA Approved Antiretroviral Therapy (see list below)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2012-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFDA Approved Antiretroviral Therapy (see list below)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

    NCT01077557 · start 2006-11

    Registered record
    Registry ID
    NCT01077557
    Conditions
    Fracture; Infection, Human Immunodeficiency Virus
    Interventions
    No Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug Exposure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-11
    Completion
    2011-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFracture; Infection, Human Immunodeficiency Virus
    InterventionNo Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug Exposure
    PhaseNot recorded
    Registry statusCompleted

  • A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

    NCT00335270 · start 2006-03

    Registered record
    Registry ID
    NCT00335270
    Conditions
    HIV
    Interventions
    fos-amprenavir calcium, ritonavir; abacavir/lamivudine as Epzicom
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionfos-amprenavir calcium, ritonavir; abacavir/lamivudine as Epzicom
    PhasePhase 4
    Registry statusCompleted

  • The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

    NCT00259727 · start 2006-01

    Registered record
    Registry ID
    NCT00259727
    Conditions
    Diabetes; HIV Infections; Insulin Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2008-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; HIV Infections; Insulin Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir

    NCT00148785 · start 2005-07

    Registered record
    Registry ID
    NCT00148785
    Conditions
    HIV Infections
    Interventions
    Indinavir/Ritonavir/Fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-07
    Completion
    2007-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir/Ritonavir/Fosamprenavir
    PhasePhase 4
    Registry statusCompleted

  • Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

    NCT00071760 · start 2003-10-23

    Registered record
    Registry ID
    NCT00071760
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    GW433908; ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10-23
    Completion
    2022-03-29
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionGW433908; ritonavir
    PhasePhase 2
    Registry statusCompleted

  • Fosamprenavir Expanded Access

    NCT00240552 · start 2003-07

    Registered record
    Registry ID
    NCT00240552
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    fosamprenavir; Telzir®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-07
    Completion
    2005-08
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventionfosamprenavir; Telzir®
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

    NCT00056641 · start 2003-02-18

    Registered record
    Registry ID
    NCT00056641
    Conditions
    HIV Infections
    Interventions
    tipranavir; ritonavir; saquinavir; amprenavir; lopinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-02-18
    Completion
    Not recorded
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventiontipranavir; ritonavir; saquinavir; amprenavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

    NCT00192660 · start 2003-02

    Registered record
    Registry ID
    NCT00192660
    Conditions
    HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease
    Interventions
    Lamivudine; Stavudine; Didanosine; Zidovudine; Tenofovir; Abacavir; Efavirenz (EFV); Nevirapine; Indinavir; Saquinavir; Amprenavir; Ritonavir; Nelfinavir; Tipranavir; enfuvirtide (T20)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-02
    Completion
    2007-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease
    InterventionLamivudine; Stavudine; Didanosine; Zidovudine +11 more
    PhasePhase 4
    Registry statusCompleted

  • Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

    NCT00039741 · start 2002-08

    Registered record
    Registry ID
    NCT00039741
    Conditions
    HIV Infections
    Interventions
    NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT); NNRTIs (EFV, NVP); PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2010-03
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT); NNRTIs (EFV, NVP); PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
    PhasePhase 2 / Phase 3
    Registry statusCompleted